BioCentury | May 31, 2018
Emerging Company Profile

Oral route for HAE

The team behind Firazyr icatibant has reunited to develop an oral version of the drug that could give hereditary angioedema patients the alternative to injectables they’ve been asking for. Pharvaris B.V. brings together team members...
BioCentury | Nov 10, 2017
Financial News

Exicure raises additional $11.2M in private placement

...led by Luye Pharma Group and included participation from fellow new investors Eager Info Investments, Knoll...
BioCentury | Nov 6, 2017
Financial News

Exicure raises additional $11.2M in private placement

...led by Luye Pharma Group and included participation from fellow new investors Eager Info Investments, Knoll...
BioCentury | Mar 10, 2017
Financial News

Biohaven Pharmaceuticals completes venture financing

...raised to $80 million. RA Capital Management, Vivo Capital, Aisling Capital , Rock Springs Capital, Knoll...
BioCentury | Nov 5, 2016
Finance

Craving Biohaven

...round and was joined by RA Capital, Vivo Capital, Aisling Capital , Rock Springs Capital, Knoll...
BioCentury | Nov 4, 2016
Financial News

Biohaven completes venture financing

...Venrock. RA Capital Management, Vivo Capital, Aisling Capital , Rock Springs Capital, John W. Childs, Knoll...
BioCentury | Nov 1, 2016
Financial News

Biohaven raises $80M round

...participants included RA Capital, Vivo Capital, Aisling Capital , Rock Springs Capital, John W. Childs, Knoll...
BioCentury | Mar 17, 2016
Distillery Therapeutics

Therapeutics: Tumor necrosis factor (TNF)

Infectious disease INDICATION: Viral infection Patient sample and mouse studies suggest TNF inhibitors could help treat chronic viral infections involving loss of CD4+ T cell function. In blood from HIV patient samples and a mouse...
BioCentury | Nov 16, 2015
Company News

Emisphere, Novo Nordisk deal

Emisphere granted Novo Nordisk worldwide rights to develop and commercialize oral formulations of four classes of Novo’s products, including those for diabetes and obesity, using Emisphere’s oral Eligen technology. Emisphere granted Novo exclusive rights to...
BioCentury | Apr 6, 2015
Financial News

PlasmaTech Biopharmaceuticals completes private placement

...placement Raised: $5 million Shares: 1.7 million Price: $3 Shares after offering: 21.7 million Investor: Knoll...
Items per page:
1 - 10 of 210
BioCentury | May 31, 2018
Emerging Company Profile

Oral route for HAE

The team behind Firazyr icatibant has reunited to develop an oral version of the drug that could give hereditary angioedema patients the alternative to injectables they’ve been asking for. Pharvaris B.V. brings together team members...
BioCentury | Nov 10, 2017
Financial News

Exicure raises additional $11.2M in private placement

...led by Luye Pharma Group and included participation from fellow new investors Eager Info Investments, Knoll...
BioCentury | Nov 6, 2017
Financial News

Exicure raises additional $11.2M in private placement

...led by Luye Pharma Group and included participation from fellow new investors Eager Info Investments, Knoll...
BioCentury | Mar 10, 2017
Financial News

Biohaven Pharmaceuticals completes venture financing

...raised to $80 million. RA Capital Management, Vivo Capital, Aisling Capital , Rock Springs Capital, Knoll...
BioCentury | Nov 5, 2016
Finance

Craving Biohaven

...round and was joined by RA Capital, Vivo Capital, Aisling Capital , Rock Springs Capital, Knoll...
BioCentury | Nov 4, 2016
Financial News

Biohaven completes venture financing

...Venrock. RA Capital Management, Vivo Capital, Aisling Capital , Rock Springs Capital, John W. Childs, Knoll...
BioCentury | Nov 1, 2016
Financial News

Biohaven raises $80M round

...participants included RA Capital, Vivo Capital, Aisling Capital , Rock Springs Capital, John W. Childs, Knoll...
BioCentury | Mar 17, 2016
Distillery Therapeutics

Therapeutics: Tumor necrosis factor (TNF)

Infectious disease INDICATION: Viral infection Patient sample and mouse studies suggest TNF inhibitors could help treat chronic viral infections involving loss of CD4+ T cell function. In blood from HIV patient samples and a mouse...
BioCentury | Nov 16, 2015
Company News

Emisphere, Novo Nordisk deal

Emisphere granted Novo Nordisk worldwide rights to develop and commercialize oral formulations of four classes of Novo’s products, including those for diabetes and obesity, using Emisphere’s oral Eligen technology. Emisphere granted Novo exclusive rights to...
BioCentury | Apr 6, 2015
Financial News

PlasmaTech Biopharmaceuticals completes private placement

...placement Raised: $5 million Shares: 1.7 million Price: $3 Shares after offering: 21.7 million Investor: Knoll...
Items per page:
1 - 10 of 210